Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Elsevier Acquires Aureus Sciences, Provider of Databases and Information Tools for Pharmaceutical and Biotech Companies



Elsevier Acquires Aureus Sciences, Provider of Databases and Information Tools
                   for Pharmaceutical and Biotech Companies

  PR Newswire

  AMSTERDAM, January 8, 2013

AMSTERDAM, January 8, 2013 /PRNewswire/ --

 Elsevier to expand its suite of solutions to cover the entire drug discovery
     and development value chain by launching new life sciences solutions

Elsevier , a world-leading provider of scientific, technical and medical
information products and services, announced today the acquisition of Aureus
Sciences , a Paris, France based privately held company that provides
databases and information tools to pharmaceutical and biotech companies.

Formed in 2002, Aureus Sciences gathers unique and high quality quantitative
biological activity data for major therapeutic drug targets. This content
enables researchers to identify the most promising compounds, repurpose
existing compounds and identify targets with which the new compounds might
interact.

"The acquisition of Aureus Sciences provides us with tremendous opportunities
to generate more value for our customers," said Mark van Mierle, Managing
Director Elsevier Pharmaceutical and Biotech Group. "With the combination of
Aureus content assets and the content already available by Elsevier, we can
create a valuable solution for those in need of improving speed and accuracy
of lead-finding, decision-making and other key processes."

The acquisition enables the combination of high quality and deeply extracted
content from both companies to launch new solutions for our Pharmaceutical and
Biotech customers. The first evidence of this will be seen early this year
with the release of a new medicinal chemistry solution.

"The integration of Aureus into Elsevier, and the consolidation of best in
class content, will complement Elsevier's leadership in biomedical disciplines
and strengthen our ability to offer new innovative databases to researchers in
medicinal chemistry and pharmacology," said Jason Theodosiou, CEO of Aureus
Sciences.  "We will see many positive synergies resulting from this
combination."

The acquisition is effective immediately and financial terms of the
transaction are not being disclosed.

About Aureus Sciences

Headquartered in Paris, Aureus Sciences provides scientific databases and
software applications for researchers involved in the drug discovery and
development process. Furthermore, the company focuses on providing solutions
to the needs of pharmaceutical and biotech companies to leverage information
and knowledge as a decision making tool and to increase the speed and
efficiency of their drug discovery and development process. Over the course of
10 years and with a significant investment, the Company has developed a unique
Knowledge Production Platform which analyzes, indexes, and organizes critical
chemical and bioactivity information into databases.

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical
information products and services. The company works in partnership with the
global science and health communities to publish more than 2,000 journals,
including The Lancet and Cell , and close to 20,000 book titles, including
major reference works from Mosby and Saunders. Elsevier's online solutions
include ScienceDirect , Scopus , Reaxys , ClinicalKey and Mosby's Nursing
Suite , which enhance the productivity of science and health professionals,
and the SciVal suite and MEDai's Pinpoint Review , which help research and
health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people
worldwide. The company is part of Reed Elsevier Group PLC , a world-leading
provider of professional information solutions in the Science, Medical, Legal
and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and
Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London
Stock Exchange), RUK and ENL (New York Stock Exchange).

Media Contact Christopher Capot Director, Corporate Relations Elsevier
+1-212-633-3164 c.capot@elsevier.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement